About Ionis Pharmaceuticals (NASDAQ:IONS)
Ionis Pharmaceuticals, Inc. is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company's segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners. The Akcea Therapeutics segment includes the operations of the Company's subsidiary, Akcea Therapeutics, Inc. (Akcea Therapeutics). Akcea Therapeutics is focused on developing and commercializing volanesorsen and other clinical-stage drugs for serious cardiometabolic diseases caused by lipid disorders. The Company is developing volanesorsen to treat two severe and rare, genetically defined diseases, familial chylomicronemia (FCS) and familial partial lipodystrophy (FPL). The Company offers SPINRAZA, a Generation 2.0+ antisense drug.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology & Medical Research
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:IONS
- CUSIP: 46433010
- Web: www.ionispharma.com
Capitalization:- Market Cap: $7.94 billion
- Outstanding Shares: 124,354,000
Average Prices:- 50 Day Moving Avg: $54.75
- 200 Day Moving Avg: $49.79
- 52 Week Range: $24.58 - $64.19
P/E:- Trailing P/E Ratio: 293.99
- Foreward P/E Ratio: 912.14
- P/E Growth: -8.80
Sales & Book Value:- Annual Revenue: $485.73 million
- Price / Sales: 16.35
- Book Value: $1.74 per share
- Price / Book: 36.70
Profitability:- EBITDA: $80.88 million
- Net Margins: 5.25%
- Return on Equity: 15.52%
- Return on Assets: 2.59%
Debt:- Debt-to-Equity Ratio: 2.47%
- Current Ratio: 5.03%
- Quick Ratio: 5.00%
Misc:- Average Volume: 1.24 million shs.
- Beta: 3.12
- Short Ratio: 7.99
Frequently Asked Questions for Ionis Pharmaceuticals (NASDAQ:IONS)
What is Ionis Pharmaceuticals' stock symbol?
Ionis Pharmaceuticals trades on the NASDAQ under the ticker symbol "IONS."
How were Ionis Pharmaceuticals' earnings last quarter?
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) issued its quarterly earnings data on Tuesday, August, 8th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.06) by $0.03. The business earned $104.15 million during the quarter, compared to analysts' expectations of $93.29 million. Ionis Pharmaceuticals had a return on equity of 15.52% and a net margin of 5.25%. The company's quarterly revenue was up 170.7% on a year-over-year basis. During the same quarter last year, the business posted ($0.47) EPS. View Ionis Pharmaceuticals' Earnings History.
When will Ionis Pharmaceuticals make its next earnings announcement?
Where is Ionis Pharmaceuticals' stock going? Where will Ionis Pharmaceuticals' stock price be in 2017?
14 brokerages have issued twelve-month target prices for Ionis Pharmaceuticals' stock. Their predictions range from $18.00 to $69.00. On average, they expect Ionis Pharmaceuticals' share price to reach $49.62 in the next twelve months. View Analyst Ratings for Ionis Pharmaceuticals.
What are analysts saying about Ionis Pharmaceuticals stock?
Here are some recent quotes from research analysts about Ionis Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Ionis Pharmaceuticals, Inc. is a RNA-targeted drug discovery and development company which focuses on developing drugs for severe and rare diseases. Ionis Pharmaceuticals, Inc., formerly known as Isis Pharmaceuticals, Inc., is headquartered in Carlsbad, California. " (10/17/2017)
- 2. BMO Capital Markets analysts commented, " We maintain our Outperform rating, but decrease our price target to $59 from $63, following Phase III volanesorsen FCS data that showed strong efficacy, but higher frequency of platelet monitoring to maintain treatment. While we believe volanesorsen will be approved, biweekly monitoring and injection site reactions (ISRs) could limit patient adherence to therapy, leading us to decrease our compliance/ persistence rate to 75% from 85%. Our market share assumptions remain unchanged, given the disease burden and limited treatment options. We estimate Volanesorsen WW peak sales of $820 million." (3/7/2017)
- 3. Needham & Company LLC analysts commented, "Akcea, a wholly owned subsidiary of Ionis Pharmaceuticals, reported that volanesorsen met its primary endpoint of triglyceride lowering in the Phase III APPROACH study in patients with familial chylomicronemia syndrome (FCS). A surprise positive, the study also demonstrated significant reductions in pancreatic attacks and abdominal pain. However, IONS shares are reacting negatively this morning because of the reported incidence of discontinuations for thrombocytopenia. We view the sell off as an over reaction considering that the platelet reductions are disease related and rgw study discontinuations stopped occurring after monitoring was implemented. We maintain our Buy rating on IONS." (3/6/2017)
- 4. Cowen and Company analysts commented, "Ionis provided an update on its pipeline of ~40 antisense drug candidates." (1/6/2017)
Are investors shorting Ionis Pharmaceuticals?
Ionis Pharmaceuticals saw a decline in short interest in September. As of September 15th, there was short interest totalling 10,235,812 shares, a decline of 11.1% from the August 31st total of 11,514,444 shares. Based on an average daily trading volume, of 948,653 shares, the short-interest ratio is currently 10.8 days. Currently, 8.3% of the shares of the stock are sold short.
Who are some of Ionis Pharmaceuticals' key competitors?
Some companies that are related to Ionis Pharmaceuticals include Alnylam Pharmaceuticals (ALNY), Seattle Genetics (SGEN), Alkermes PLC (ALKS), Qiagen N.V. (QGEN), Icon Plc (ICLR), Exact Sciences Corporation (EXAS), Charles River Laboratories International (CRL), United Therapeutics Corporation (UTHR), PRA Health Sciences (PRAH), Puma Biotechnology (PBYI), BIO-TECHNE Corp (TECH), ACADIA Pharmaceuticals (ACAD), PAREXEL International Corporation (PRXL), FibroGen (FGEN), Nektar Therapeutics (NKTR), WuXi PharmaTech (Cayman) (WX), Ligand Pharmaceuticals Incorporated (LGND) and INC Research Holdings (INCR).
Who are Ionis Pharmaceuticals' key executives?
Ionis Pharmaceuticals' management team includes the folowing people:
- Stanley T. Crooke M.D. Ph.D., Chairman of the Board, President, Chief Executive Officer
- Elizabeth L. Hougen, Chief Financial Officer, Senior Vice President - Finance
- B. Lynne Parshall J.D., Chief Operating Officer, Corporate Secretary, Director
- Patrick R. O'Neil Esq., Senior Vice President, Legal, General Counsel, Chief Compliance Officer and Corporate Secretary
- C. Frank Frank Bennett Ph.D., Senior Vice President - Antisense Research
- Richard S. Geary Ph.D., Senior Vice President - Development
- Brett P. Monia Ph.D., Senior Vice President - Drug Discovery and Corporate Development
- Sarah Boyce, Chief Business Officer
- Spencer R. Berthelsen M.D., Independent Director
- Breaux B. Castleman, Independent Director
How do I buy Ionis Pharmaceuticals stock?
Shares of Ionis Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Ionis Pharmaceuticals' stock price today?
One share of Ionis Pharmaceuticals stock can currently be purchased for approximately $63.85.
MarketBeat Community Rating for Ionis Pharmaceuticals (NASDAQ IONS)MarketBeat's community ratings are surveys of what our community members think about Ionis Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Ionis Pharmaceuticals (NASDAQ:IONS) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 2 Sell Ratings, 6 Hold Ratings, 6 Buy Ratings |
| Consensus Rating: | Hold (Score: 2.29) |
| Consensus Price Target: | $49.62 (22.29% downside) |
Consensus Price Target History for Ionis Pharmaceuticals (NASDAQ:IONS)
Analysts' Ratings History for Ionis Pharmaceuticals (NASDAQ:IONS)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 10/17/2017 | Needham & Company LLC | Reiterated Rating | Buy | $64.00 | N/A |  |
| 10/13/2017 | Stifel Nicolaus | Reiterated Rating | Hold | $50.00 | N/A | |
| 10/6/2017 | Goldman Sachs Group, Inc. (The) | Reiterated Rating | Sell -> Sell | $30.00 | N/A | |
| 10/2/2017 | BMO Capital Markets | Reiterated Rating | Outperform | $69.00 | Medium | |
| 9/21/2017 | Barclays PLC | Lower Price Target | Equal Weight | $55.00 -> $52.00 | Low | |
| 8/16/2017 | Evercore ISI | Initiated Coverage | Outperform -> Outperform | $65.00 | Low | |
| 8/14/2017 | Laidlaw | Reiterated Rating | Buy | $65.00 | Low | |
| 8/10/2017 | Jefferies Group LLC | Reiterated Rating | Underperform | $17.00 -> $18.00 | High | |
| 7/27/2017 | Sanford C. Bernstein | Initiated Coverage | Market Perform | $57.00 | High | |
| 5/22/2017 | Cowen and Company | Reiterated Rating | Market Perform | | Low | |
| 5/17/2017 | Leerink Swann | Reiterated Rating | Outperform | $47.00 -> $45.00 | Medium | |
| 5/10/2017 | Piper Jaffray Companies | Set Price Target | Buy | $66.00 -> $51.00 | Low | |
| 1/5/2017 | Janney Montgomery Scott | Set Price Target | Hold | $44.00 | N/A | |
| 11/10/2016 | J P Morgan Chase & Co | Reiterated Rating | Hold | $35.00 | N/A | |
| 9/11/2016 | Wells Fargo & Company | Reiterated Rating | Buy | | N/A | |
| 8/2/2016 | Morgan Stanley | Initiated Coverage | Equal -> Equal Weight | $37.00 -> $37.00 | N/A | |
(Data available from 10/17/2015 forward)
Earnings History for Ionis Pharmaceuticals (NASDAQ:IONS)Earnings History by Quarter for Ionis Pharmaceuticals (NASDAQ IONS)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/7/2017 | | ($0.06) | | | | | N/A | |
| 8/8/2017 | Q2 2017 | ($0.06) | ($0.09) | $93.29 million | $104.15 million | View | Listen | |
| 5/9/2017 | Q1 2017 | ($0.10) | $0.03 | $86.03 million | $110.30 million | View | Listen | |
| 2/28/2017 | Q416 | ($0.20) | $0.33 | $97.47 million | $160.30 million | View | Listen | |
| 11/9/2016 | Q316 | $0.07 | $0.06 | $114.65 million | $110.90 million | View | Listen | |
| 8/9/2016 | Q216 | ($0.52) | ($0.47) | $38.52 million | $38.50 million | View | N/A | |
| 5/4/2016 | Q116 | ($0.50) | ($0.52) | $36.21 million | $36.90 million | View | N/A | |
| 2/25/2016 | Q415 | ($0.47) | ($0.59) | $49.32 million | $51.60 million | View | Listen | |
| 11/9/2015 | Q315 | ($0.31) | ($0.30) | $52.93 million | $49.10 million | View | N/A | |
| 8/4/2015 | Q215 | $0.29 | $0.29 | $114.93 million | $120.40 million | View | N/A | |
| 5/5/2015 | Q115 | ($0.19) | ($0.14) | $52.74 million | $62.60 million | View | N/A | |
| 2/27/2015 | Q414 | $0.12 | $0.25 | $74.58 million | $84.90 million | View | N/A | |
| 11/7/2014 | Q314 | ($0.20) | ($0.23) | $45.79 million | $44.10 million | View | N/A | |
| 8/4/2014 | Q214 | ($0.12) | ($0.10) | $45.60 million | $57.08 million | View | N/A | |
| 5/6/2014 | Q114 | ($0.23) | ($0.27) | $35.12 million | $28.20 million | View | N/A | |
| 2/28/2014 | Q413 | ($0.17) | ($0.21) | $34.20 million | $42.25 million | View | N/A | |
| 11/5/2013 | Q313 | ($0.27) | ($0.21) | $19.82 million | $23.60 million | View | N/A | |
| 8/6/2013 | Q2 2013 | ($0.21) | ($0.09) | $26.76 million | $38.10 million | View | Listen | |
| 5/7/2013 | Q1 2013 | ($0.02) | ($0.02) | $45.24 million | $43.36 million | View | Listen | |
| 2/28/2013 | Q4 2012 | ($0.23) | ($0.03) | $15.78 million | $19.90 million | View | Listen | |
| 11/6/2012 | Q312 | ($0.26) | ($0.37) | $23.11 million | $11.60 million | View | N/A | |
| 8/6/2012 | | ($0.08) | ($0.01) | | | View | N/A | |
| 5/8/2012 | | ($0.28) | ($0.24) | | | View | N/A | |
| 2/29/2012 | | ($0.13) | ($0.20) | | | View | N/A | |
| 11/7/2011 | | ($0.20) | ($0.27) | | | View | N/A | |
| 8/4/2011 | | ($0.22) | ($0.18) | | | View | N/A | |
| 5/5/2011 | | ($0.19) | ($0.20) | | | View | N/A | |
| 2/28/2011 | | ($0.22) | ($0.14) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Ionis Pharmaceuticals (NASDAQ:IONS)2017 EPS Consensus Estimate: $0.13
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 2 | ($0.06) | $0.16 | $0.05 |
| Q2 2017 | 2 | ($0.38) | $0.19 | ($0.10) |
| Q3 2017 | 2 | $0.07 | $0.22 | $0.15 |
| Q4 2017 | 2 | ($0.17) | $0.23 | $0.03 |
(Data provided by Zacks Investment Research)
Dividend History for Ionis Pharmaceuticals (NASDAQ:IONS)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Ionis Pharmaceuticals (NASDAQ:IONS)Insider Ownership Percentage: 2.13%
Institutional Ownership Percentage: 89.24%
Insider Trades by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 10/13/2017 | Richard S Geary | SVP | Sell | 8,268 | $60.00 | $496,080.00 | |
| 10/13/2017 | Stanley T Crooke | Chairman | Sell | 16,500 | $59.46 | $981,090.00 | |
| 10/5/2017 | Patrick R O'neil | SVP | Sell | 1,000 | $55.00 | $55,000.00 | |
| 10/4/2017 | Stanley T Crooke | Chairman | Sell | 27,500 | $52.89 | $1,454,475.00 | |
| 10/2/2017 | Stanley T Crooke | CEO | Sell | 15,000 | $52.00 | $780,000.00 | |
| 9/6/2017 | Patrick R O'neil | SVP | Sell | 1,000 | $55.00 | $55,000.00 | |
| 7/24/2017 | C Frank Bennett | SVP | Sell | 10,000 | $59.29 | $592,900.00 | |
| 7/20/2017 | Stanley T Crooke | Chairman | Sell | 11,000 | $55.35 | $608,850.00 | |
| 7/19/2017 | Ionis Pharmaceuticals Inc | Major Shareholder | Buy | 3,125,000 | $8.00 | $25,000,000.00 | |
| 7/17/2017 | Stanley T Crooke | Chairman | Sell | 16,500 | $52.45 | $865,425.00 | |
| 7/3/2017 | Brett P Monia | SVP | Sell | 309 | $51.35 | $15,867.15 | |
| 7/3/2017 | Stanley T Crooke | Chairman | Sell | 16,500 | $52.10 | $859,650.00 | |
| 6/1/2017 | Patrick R O'neil | SVP | Sell | 70 | $48.00 | $3,360.00 | |
| 5/1/2017 | Patrick R O'neil | SVP | Sell | 650 | $48.75 | $31,687.50 | |
| 4/25/2017 | Stanley T Crooke | Chairman | Sell | 16,500 | $47.81 | $788,865.00 | |
| 4/24/2017 | Patrick R O'neil | SVP | Sell | 500 | $45.00 | $22,500.00 | |
| 4/19/2017 | Stanley T Crooke | Chairman | Sell | 5,500 | $43.25 | $237,875.00 | |
| 4/13/2017 | Stanley T Crooke | Chairman | Sell | 22,000 | $40.69 | $895,180.00 | |
| 4/12/2017 | Patrick R O'neil | SVP | Sell | 1,000 | $40.07 | $40,070.00 | |
| 3/3/2017 | C Frank Bennett | SVP | Sell | 5,000 | $55.00 | $275,000.00 | |
| 3/1/2017 | B Lynne Parshall | COO | Sell | 4,625 | $49.26 | $227,827.50 | |
| 3/1/2017 | Patrick R O'neil | SVP | Sell | 1,500 | $49.29 | $73,935.00 | |
| 2/6/2017 | Patrick R O'neil | SVP | Sell | 1,500 | $46.17 | $69,255.00 | |
| 1/17/2017 | B Lynne Parshall | COO | Sell | 7,246 | $46.29 | $335,417.34 | |
| 1/17/2017 | Brett P Monia | SVP | Sell | 2,502 | $46.29 | $115,817.58 | |
| 1/17/2017 | Elizabeth L Hougen | CFO | Sell | 2,273 | $46.29 | $105,217.17 | |
| 1/17/2017 | Sarah Boyce | Insider | Sell | 1,361 | $46.29 | $63,000.69 | |
| 1/17/2017 | Stanley T Crooke | CEO | Sell | 15,382 | $46.29 | $712,032.78 | |
| 1/10/2017 | Stanley T Crooke | Chairman | Sell | 13,200 | $49.25 | $650,100.00 | |
| 1/4/2017 | Stanley T Crooke | Chairman | Sell | 18,700 | $48.89 | $914,243.00 | |
| 1/3/2017 | Brett P Monia | SVP | Sell | 309 | $48.60 | $15,017.40 | |
| 12/20/2016 | Brett P Monia | SVP | Sell | 130 | $52.48 | $6,822.40 | |
| 12/15/2016 | B Lynne Parshall | COO | Sell | 4,000 | $50.00 | $200,000.00 | |
| 12/5/2016 | Elizabeth L Hougen | CFO | Sell | 2,500 | $46.05 | $115,125.00 | |
| 12/5/2016 | Patrick R O'neil | SVP | Sell | 350 | $45.00 | $15,750.00 | |
| 12/1/2016 | B Lynne Parshall | COO | Sell | 12,500 | $42.23 | $527,875.00 | |
| 11/14/2016 | Patrick R O'neil | SVP | Sell | 1,000 | $45.00 | $45,000.00 | |
| 11/11/2016 | Elizabeth L Hougen | SVP | Sell | 5,000 | $39.75 | $198,750.00 | |
| 11/7/2016 | C Frank Bennett | SVP | Sell | 5,000 | $34.00 | $170,000.00 | |
| 10/5/2016 | Stanley T Crooke | Chairman | Sell | 11,000 | $36.61 | $402,710.00 | |
| 9/27/2016 | Stanley T Crooke | Chairman | Sell | 22,000 | $36.02 | $792,440.00 | |
| 9/21/2016 | Stanley T Crooke | Chairman | Sell | 22,000 | $35.50 | $781,000.00 | |
| 9/1/2016 | B Lynne Parshall | COO | Sell | 12,500 | $29.88 | $373,500.00 | |
| 5/31/2016 | Frederick T Muto | Director | Sell | 12,500 | $22.31 | $278,875.00 | |
| 4/6/2016 | Patrick R O'neil | SVP | Sell | 1,000 | $45.00 | $45,000.00 | |
| 4/6/2016 | Stanley T Crooke | CEO | Sell | 11,000 | $46.13 | $507,430.00 | |
| 3/31/2016 | Stanley T Crooke | CEO | Sell | 11,000 | $40.74 | $448,140.00 | |
| 3/23/2016 | Patrick R O'neil | SVP | Sell | 1,000 | $45.40 | $45,400.00 | |
| 1/19/2016 | B Lynne Parshall | COO | Sell | 5,192 | $41.46 | $215,260.32 | |
| 1/19/2016 | C Frank Bennett | SVP | Sell | 2,110 | $41.46 | $87,480.60 | |
| 1/19/2016 | Elizabeth L. Hougen | CFO | Sell | 1,899 | $41.46 | $78,732.54 | |
| 1/19/2016 | Sarah Boyce | insider | Sell | 872 | $41.46 | $36,153.12 | |
| 1/19/2016 | Stanley T. Crooke | CEO | Sell | 13,401 | $41.46 | $555,605.46 | |
| 1/5/2016 | Stanley T. Crooke | CEO | Sell | 5,500 | $62.10 | $341,550.00 | |
| 1/4/2016 | B Lynne Parshall | COO | Sell | 809 | $61.05 | $49,389.45 | |
| 1/4/2016 | Brett P. Monia | SVP | Sell | 127 | $61.00 | $7,747.00 | |
| 1/4/2016 | Stanley T. Crooke | CEO | Sell | 11,000 | $61.05 | $671,550.00 | |
| 12/16/2015 | C Frank Bennett | SVP | Sell | 7,909 | $57.41 | $454,055.69 | |
| 12/1/2015 | Patrick R. O'neil | SVP | Sell | 1,000 | $61.50 | $61,500.00 | |
| 11/11/2015 | Joseph Klein III | Director | Sell | 6,875 | $64.18 | $441,237.50 | |
| 11/10/2015 | C Frank Bennett | SVP | Sell | 5,000 | $64.00 | $320,000.00 | |
| 11/6/2015 | C Frank Bennett | SVP | Sell | 5,000 | $56.00 | $280,000.00 | |
| 11/3/2015 | Patrick R. O'neil | SVP | Sell | 1,000 | $51.95 | $51,950.00 | |
| 10/23/2015 | Stanley T. Crooke | CEO | Sell | 44,000 | $43.85 | $1,929,400.00 | |
| 10/2/2015 | B Lynne Parshall | COO | Sell | 12,436 | $40.75 | $506,767.00 | |
| 7/6/2015 | B Lynne Parshall | COO | Sell | 6,218 | $57.01 | $354,488.18 | |
| 7/6/2015 | Stanley T Crooke | CEO | Sell | 5,000 | $57.01 | $285,050.00 | |
| 7/1/2015 | B Lynne Parshall | COO | Sell | 6,218 | $57.56 | $357,908.08 | |
| 7/1/2015 | Stanley T Crooke | CEO | Sell | 6,175 | $57.56 | $355,433.00 | |
| 6/8/2015 | Brett P Monia | SVP | Sell | 7,600 | $66.22 | $503,272.00 | |
| 4/7/2015 | B Lynne Parshall | COO | Sell | 5,565 | $63.07 | $350,984.55 | |
| 4/7/2015 | Stanley T Crooke | CEO | Sell | 22,377 | $63.07 | $1,411,317.39 | |
| 3/24/2015 | C Frank Bennett | SVP | Sell | 15,000 | $70.61 | $1,059,150.00 | |
| 3/19/2015 | Elizabeth L Hougen | CFO | Sell | 10,000 | $73.33 | $733,300.00 | |
| 3/19/2015 | Patrick R O'neil | SVP | Sell | 30,525 | $74.85 | $2,284,796.25 | |
| 3/2/2015 | Joseph H Wender | Director | Sell | 7,000 | $65.97 | $461,790.00 | |
| 1/27/2015 | Stanley T Crooke | CEO | Sell | 11,000 | $72.93 | $802,230.00 | |
| 1/16/2015 | B Lynne Parshall | COO | Sell | 4,093 | $67.96 | $278,160.28 | |
| 1/16/2015 | Elizabeth L Hougen | CFO | Sell | 1,291 | $67.96 | $87,736.36 | |
| 1/16/2015 | Richard S Geary | SVP | Sell | 1,543 | $67.96 | $104,862.28 | |
| 1/16/2015 | Stanley T Crooke | CEO | Sell | 9,054 | $67.96 | $615,309.84 | |
| 1/9/2015 | Stanley T Crooke | CEO | Sell | 11,000 | $73.57 | $809,270.00 | |
| 1/7/2015 | Stanley T Crooke | CEO | Sell | 22,000 | $67.04 | $1,474,880.00 | |
| 1/2/2015 | B Lynne Parshall | COO | Sell | 11,200 | $62.12 | $695,744.00 | |
| 1/2/2015 | Patrick R O'neil | SVP | Sell | 1,500 | $62.12 | $93,180.00 | |
| 12/1/2014 | Patrick R O'neil | SVP | Sell | 1,500 | $51.21 | $76,815.00 | |
| 11/3/2014 | Patrick R O'neil | SVP | Sell | 1,500 | $46.17 | $69,255.00 | |
| 10/30/2014 | B Lynne Parshall | COO | Sell | 11,071 | $45.12 | $499,523.52 | |
| 10/23/2014 | Stanley T Crooke | CEO | Sell | 14,600 | $42.22 | $616,412.00 | |
| 10/3/2014 | Stanley T Crooke | CEO | Sell | 36,000 | $38.52 | $1,386,720.00 | |
| 10/1/2014 | Patrick R O'neil | SVP | Sell | 1,500 | $38.04 | $57,060.00 | |
| 10/1/2014 | Stanley T Crooke | CEO | Sell | 20,000 | $37.91 | $758,200.00 | |
| 8/27/2014 | C Frank Bennett | SVP | Sell | 5,000 | $40.53 | $202,650.00 | |
| 8/13/2014 | Stanley T Crooke | CEO | Sell | 15,500 | $35.45 | $549,475.00 | |
| 8/12/2014 | Patrick R O'neil | SVP | Sell | 1,500 | $35.00 | $52,500.00 | |
| 8/1/2014 | Stanley T Crooke | CEO | Sell | 16,000 | $30.53 | $488,480.00 | |
| 7/31/2014 | Brett P Monia | SVP | Sell | 79 | $31.50 | $2,488.50 | |
| 7/1/2014 | Patrick R O'neil | SVP | Sell | 1,500 | $35.33 | $52,995.00 | |
| 7/1/2014 | Stanley T Crooke | CEO | Sell | 17,500 | $35.57 | $622,475.00 | |
| 6/23/2014 | C Frank Bennett | SVP | Sell | 11,200 | $36.78 | $411,936.00 | |
| 6/19/2014 | Stanley T Crooke | CEO | Sell | 11,000 | $35.10 | $386,100.00 | |
| 6/10/2014 | Stanley T Crooke | CEO | Sell | 11,000 | $33.46 | $368,060.00 | |
| 6/2/2014 | Frederick T Muto | Director | Sell | 10,000 | $28.59 | $285,900.00 | |
| 4/2/2014 | Stanley Crooke | CEO | Sell | 8,800 | $43.65 | $384,120.00 | |
| 1/30/2014 | B Lynne Parshall | COO | Sell | 89,510 | $49.49 | $4,429,849.90 | |
| 1/24/2014 | Joseph Klein III | Director | Sell | 10,313 | $48.66 | $501,830.58 | |
| 1/22/2014 | Joseph Wender | Director | Sell | 10,000 | $50.98 | $509,800.00 | |
| 1/22/2014 | Richard Geary | SVP | Sell | 22,200 | $50.05 | $1,111,110.00 | |
| 1/16/2014 | B Lynne Parshall | COO | Sell | 1,641 | $47.08 | $77,258.28 | |
| 1/16/2014 | Stanley Crooke | CEO | Sell | 3,527 | $47.08 | $166,051.16 | |
| 1/8/2014 | Richard Geary | SVP | Sell | 15,000 | $40.45 | $606,750.00 | |
| 1/8/2014 | Stanley Crooke | CEO | Sell | 12,500 | $40.05 | $500,625.00 | |
| 1/2/2014 | Stanley Crooke | CEO | Sell | 31,500 | $39.35 | $1,239,525.00 | |
| 12/26/2013 | B Lynne Parshall | COO | Sell | 37,811 | $40.91 | $1,546,848.01 | |
| 12/24/2013 | B Lynne Parshall | COO | Sell | 70,000 | $41.49 | $2,904,300.00 | |
| 12/20/2013 | Joseph Wender | Director | Sell | 19,731 | $39.58 | $780,952.98 | |
| 12/5/2013 | C Frank Bennett | SVP | Sell | 10,000 | $39.92 | $399,200.00 | |
| 11/26/2013 | Joseph Wender | Director | Sell | 10,000 | $36.63 | $366,300.00 | |
| 9/20/2013 | B Lynne Parshall | COO | Sell | 90,000 | $35.43 | $3,188,700.00 | |
| 9/20/2013 | Brett Monia | SVP | Sell | 68,281 | $34.21 | $2,335,893.01 | |
| 9/20/2013 | Stanley Crooke | CEO | Sell | 58,740 | $35.19 | $2,067,060.60 | |
| 9/19/2013 | C Frank Bennett | SVP | Sell | 10,000 | $35.02 | $350,200.00 | |
| 9/11/2013 | B Lynne Parshall | COO | Sell | 63,505 | $31.04 | $1,971,195.20 | |
| 9/9/2013 | C Frank Bennett | SVP | Sell | 10,000 | $30.23 | $302,300.00 | |
| 9/4/2013 | Patrick R O'neil | SVP | Sell | 2,500 | $27.09 | $67,725.00 | |
| 8/26/2013 | Brett Monia | SVP | Sell | 2,909 | $25.58 | $74,412.22 | |
| 8/9/2013 | Joseph Klein III | Director | Sell | 18,750 | $28.22 | $529,125.00 | |
| 7/23/2013 | Stanley T Crooke | COO | Sell | 11,500 | $30.00 | $345,000.00 | |
| 7/22/2013 | Stanley T Crooke | CEO | Sell | 62,200 | $30.50 | $1,897,100.00 | |
| 7/17/2013 | Stanley T Crooke | CEO | Sell | 49,300 | $33.12 | $1,632,816.00 | |
| 7/12/2013 | Stanley T Crooke | CEO | Sell | 90,000 | $31.75 | $2,857,500.00 | |
| 7/11/2013 | Richard S Geary | SVP | Sell | 9,000 | $31.90 | $287,100.00 | |
| 7/9/2013 | Richard S Geary | SVP | Sell | 66,163 | $30.03 | $1,986,874.89 | |
| 7/9/2013 | Stanley T Crooke | CEO | Sell | 109,172 | $26.69 | $2,913,800.68 | |
| 7/3/2013 | Richard S Geary | SVP | Sell | 5,000 | $29.02 | $145,100.00 | |
| 7/1/2013 | Stanley T Crooke | CEO | Sell | 50,683 | $27.65 | $1,401,384.95 | |
| 6/26/2013 | Stanley T Crooke | CEO | Sell | 90,000 | $26.73 | $2,405,700.00 | |
| 6/25/2013 | Richard S Geary | SVP | Sell | 47,049 | $26.20 | $1,232,683.80 | |
| 6/20/2013 | Joseph H Wender | Director | Sell | 5,447 | $20.93 | $114,005.71 | |
| 6/11/2013 | Brett P Monia | SVP | Sell | 9,375 | $23.76 | $222,750.00 | |
| 5/30/2013 | Frederick T Muto | Director | Sell | 10,000 | $21.96 | $219,600.00 | |
| 1/16/2013 | Stanley T Crooke | CEO | Sell | 1,460 | $14.00 | $20,440.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Ionis Pharmaceuticals (NASDAQ:IONS)
Latest Headlines for Ionis Pharmaceuticals (NASDAQ:IONS)
| Source: |
|
| Date | Headline |
|---|
 | Ionis Pharmaceuticals, Inc. (IONS) SVP Sells $496,080.00 in Stock
www.americanbankingnews.com - October 17 at 7:28 PM |
| Stanley T. Crooke Sells 16,500 Shares of Ionis Pharmaceuticals, Inc. (IONS) Stock
www.americanbankingnews.com - October 17 at 7:26 PM |
 | Ionis Presents New Data from NEURO-TTR Study and Highlights Programs from Its Neurological Disease Franchise at ... - PR Newswire (press release)
www.prnewswire.com - October 16 at 3:41 PM |
 | Featured Company News - Ionis Pharma Commences Phase-1/2a Clinical Study of IONIS-MAPTRx for Patients with Alzheimer's Disease
finance.yahoo.com - October 16 at 3:41 PM |
| Biogen Biomarkers Mark Way To Alzheimer's, Parkinson's Treatments
finance.yahoo.com - October 16 at 3:41 PM |
| Ionis Presents New Data from NEURO-TTR Study and Highlights Programs from Its Neurological Disease Franchise at ANA Congress
finance.yahoo.com - October 15 at 6:49 PM |
 | Ionis Pharma (IONS) Commences Clinical Study of IONIS-MAPT Rx - StreetInsider.com
www.streetinsider.com - October 15 at 12:26 AM |
| Ionis Pharmaceuticals' (IONS) Hold Rating Reaffirmed at Stifel Nicolaus
www.americanbankingnews.com - October 14 at 1:30 PM |
| Ionis Pharma (IONS) Commences Clinical Study of IONIS-MAPT Rx
www.streetinsider.com - October 14 at 12:51 AM |
| Ionis Pharmaceuticals Initiates Clinical Study of IONIS-MAPT Rx in Patients with Alzheimer's Disease
finance.yahoo.com - October 13 at 7:49 PM |
| Ionis Pharmaceuticals, Inc. (IONS) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - October 7 at 3:02 PM |
| Goldman Sachs Group, Inc. (The) Reaffirms "Sell" Rating for Ionis Pharmaceuticals, Inc. (IONS)
www.americanbankingnews.com - October 7 at 12:58 AM |
| ETFs with exposure to Ionis Pharmaceuticals, Inc. : October 6, 2017
finance.yahoo.com - October 6 at 11:46 PM |
| Ionis Pharmaceuticals, Inc. (IONS) SVP Sells $55,000.00 in Stock
www.americanbankingnews.com - October 6 at 8:16 PM |
| Today's Research Reports on Trending Tickers: Ionis Pharmaceuticals and HTG Molecular Diagnostics
finance.yahoo.com - October 6 at 8:21 AM |
| Ionis Pharmaceuticals Clears Technical Benchmark, Hitting 80-Plus RS Rating
finance.yahoo.com - October 6 at 12:41 AM |
| Ionis Pharmaceuticals, Inc. :IONS-US: Earnings Analysis: Q2, 2017 By the Numbers : October 5, 2017
finance.yahoo.com - October 6 at 12:41 AM |
| $129.33 Million in Sales Expected for Ionis Pharmaceuticals, Inc. (IONS) This Quarter
www.americanbankingnews.com - October 5 at 9:46 AM |
| Insider Selling: Ionis Pharmaceuticals, Inc. (IONS) Chairman Sells 27,500 Shares of Stock
www.americanbankingnews.com - October 4 at 10:22 PM |
| Stanley T. Crooke Sells 15,000 Shares of Ionis Pharmaceuticals, Inc. (IONS) Stock
www.americanbankingnews.com - October 4 at 10:22 PM |
| Breakfast Technical Briefing on Drug Makers Stocks -- Amarin, Endo, Ionis Pharma, and Teva Pharma - PR Newswire (press release)
www.prnewswire.com - October 4 at 5:49 PM |
| Ionis Pharmaceuticals, Inc. (IONS) Expected to Post Earnings of $0.02 Per Share
www.americanbankingnews.com - October 3 at 6:20 AM |
| BMO Capital Markets Reiterates Outperform Rating for Ionis Pharmaceuticals, Inc. (IONS)
www.americanbankingnews.com - October 2 at 2:36 PM |
| Ionis Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : IONS-US : October 2, 2017
finance.yahoo.com - October 2 at 1:04 PM |
| Ionis Pharmaceuticals, Inc. (IONS) Sees Significant Decrease in Short Interest
www.americanbankingnews.com - September 29 at 1:28 AM |
| Alnylam Is Entering 'New Chapter,' But Ionis Still Has A Chance
finance.yahoo.com - September 22 at 1:50 PM |
| Ionis Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : IONS-US : September 22, 2017
finance.yahoo.com - September 22 at 1:50 PM |
| Barclays PLC Trims Ionis Pharmaceuticals, Inc. (IONS) Target Price to $52.00
www.americanbankingnews.com - September 21 at 3:46 PM |
| Voyager Therapeutics (VYGR) & Ionis Pharmaceuticals (IONS) Financial Comparison
www.americanbankingnews.com - September 20 at 4:14 PM |
| Ionis Pharmaceuticals, Inc. (IONS) Stock Rating Reaffirmed by Needham & Company LLC
www.americanbankingnews.com - September 17 at 8:58 AM |
| Analyzing Brainstorm Cell Therapeutics (BCLI) and Ionis Pharmaceuticals (IONS)
www.americanbankingnews.com - September 17 at 2:31 AM |
 | Akcea and Ionis Announce Filing of New Drug Submission for Volanesorsen to Health Canada - Nasdaq
www.nasdaq.com - September 12 at 4:41 PM |
| Akcea and Ionis Announce Filing of New Drug Submission for Volanesorsen to Health Canada
finance.yahoo.com - September 12 at 4:41 PM |
| Ionis Pharmaceuticals, Inc. (IONS) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - September 12 at 2:50 PM |
| Ionis Pharmaceuticals, Inc. (IONS) Rating Reiterated by Stifel Nicolaus
www.americanbankingnews.com - September 12 at 11:22 AM |
| Ionis Pharma (IONS) Reports New Data from Clinical Program for IONIS-STAT3-2.5Rx (AZD9150) at ESCO 2017
www.streetinsider.com - September 12 at 1:43 AM |
| Ionis Pharma (IONS) Reports New Data from Clinical Program for IONIS-STAT3-2.5Rx (AZD9150) at ESCO 2017 - StreetInsider.com
www.streetinsider.com - September 11 at 6:12 AM |
| New Data Presented at European Society for Medical Oncology Meeting Demonstrate Antitumor Activity with IONIS-STAT3-2.5 Rx in Combination with Imfinzi
finance.yahoo.com - September 11 at 6:12 AM |
| Ionis Pharmaceuticals, Inc. (IONS) Receives New Coverage from Analysts at Barclays PLC
www.americanbankingnews.com - September 10 at 5:16 PM |
 | NLNK Rallies On Indoximod Data, VRNA Breathes Easy, ALNY Jolted
www.rttnews.com - September 8 at 1:19 AM |
| Insider Selling: Ionis Pharmaceuticals, Inc. (IONS) SVP Sells 1,000 Shares of Stock
www.americanbankingnews.com - September 7 at 10:24 PM |
 | Breaking Down Barclays' New Bullish Calls On Biotech - Benzinga
www.benzinga.com - September 7 at 8:16 PM |
| Today's Research Reports on Trending Tickers: Nektar Therapeutics and Ionis Pharmaceuticals Inc.
finance.yahoo.com - September 2 at 12:13 AM |
| Ionis Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : IONS-US : September 1, 2017
finance.yahoo.com - September 2 at 12:13 AM |
 | Akcea and Ionis Announce Submission of New Drug Application for Volanesorsen to the US FDA - GlobeNewswire (press release)
globenewswire.com - September 1 at 1:00 AM |
| Technology Platforms and Research Programs Drive LGND’s Partnerships
finance.yahoo.com - August 31 at 7:58 PM |
| Ionis Pharma (IONS) Earns $40M Milestone from Biogen for SPINRAZA
www.streetinsider.com - August 31 at 6:15 AM |
| Ionis Earns $40 Million SPINRAZA Regulatory Milestone Payment from Biogen
finance.yahoo.com - August 31 at 6:15 AM |
| Ionis Recommends Shareholders Reject The Below-The-Market Mini-Tender Offer By TRC Capital Corporation - PR Newswire (press release)
www.prnewswire.com - August 25 at 10:26 PM |
| Must-Know Developments for Ionis Pharmaceuticals
finance.yahoo.com - August 25 at 4:43 PM |
Ionis Pharmaceuticals (IONS) Chart for Tuesday, October, 17, 2017
